Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Heart Test Laboratories Inc. Warrant (HSCSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/29/2025: HSCSW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -62.5% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/29/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.58 | 52 Weeks Range 0.04 - 0.17 | Updated Date 03/20/2025 |
52 Weeks Range 0.04 - 0.17 | Updated Date 03/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -62.95% | Return on Equity (TTM) -163.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 995735 |
Shares Outstanding - | Shares Floating 995735 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Heart Test Laboratories Inc. Warrant
Company Overview
History and Background
Heart Test Laboratories Inc. (HSCS) is a medical technology company focused on developing and commercializing cardiovascular diagnostic products. The warrant represents the right to purchase shares of HSCS common stock under specific conditions.
Core Business Areas
- Cardiovascular Diagnostic Solutions: Develops and commercializes MyoVista, a point-of-care diagnostic platform used to detect heart disease early.
Leadership and Structure
Details on leadership structure and team are available on the company's investor relations page.
Top Products and Market Share
Key Offerings
- MyoVista: MyoVista is a point-of-care diagnostic platform, designed to detect heart disease earlier. Market share data is currently not publicly available. Competitors include traditional ECG machines and other diagnostic tools offered by companies like GE Healthcare, Philips, and Siemens Healthineers. No user data or revenues publicly known.
Market Dynamics
Industry Overview
The cardiovascular diagnostic market is a large and growing market, driven by the increasing prevalence of heart disease and the need for early and accurate diagnosis.
Positioning
Heart Test Laboratories aims to carve out a niche in the point-of-care diagnostic space with MyoVista. The company is targeting primary care physicians and other healthcare providers who can use the device to screen patients for heart disease in their offices.
Total Addressable Market (TAM)
The total addressable market is substantial, given the high prevalence of cardiovascular disease worldwide. While a specific TAM figure is not publicly available, it is positioned to capture a segment of the point-of-care diagnostics market.
Upturn SWOT Analysis
Strengths
- Point-of-care diagnostic capabilities
- Potential for early heart disease detection
- Proprietary technology (MyoVista)
Weaknesses
- Limited commercialization history
- Dependence on MyoVista adoption
- Limited financial resources
- Lack of existing market share
Opportunities
- Partnerships with healthcare providers
- Expansion into new markets
- Increased awareness of early heart disease detection
- Receive regulatory approvals
Threats
- Competition from established players
- Regulatory hurdles
- Reimbursement challenges
- Technological advancements by competitors
- Economic downturn
Competitors and Market Share
Key Competitors
- GE (GE)
- Philips (PHG)
- Siemens Healthineers (SHS)
Competitive Landscape
Heart Test Laboratories faces intense competition from established players with greater resources and broader product portfolios. However, its point-of-care focus and innovative technology could provide a competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Historical growth limited due to early stage. No data available.
Future Projections: Future projections depend on successful commercialization of MyoVista and are subject to various market risks. Analyst estimates are not widely available at this stage.
Recent Initiatives: Focus on commercializing MyoVista and securing partnerships. Details can be found in press releases and investor updates.
Summary
Heart Test Laboratories Inc. is an early-stage company with promising technology in the cardiovascular diagnostics space. The key to success lies in the successful commercialization and adoption of MyoVista. The company faces substantial competition and needs to secure financing to fuel its growth. Investors should carefully consider the risks and uncertainties associated with investing in an early-stage medical technology company.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Heart Test Laboratories Inc. Investor Relations
- SEC Filings
- Market Research Reports (limited availability)
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. The information provided is based on publicly available data and is subject to change. Investing in warrants and early-stage companies involves significant risks, including the potential loss of investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heart Test Laboratories Inc. Warrant
Exchange NASDAQ | Headquaters Southlake, TX, United States | ||
IPO Launch date 2022-06-15 | CEO, President & Chairman of the Board of Directors Mr. Andrew Simpson | ||
Sector Healthcare | Industry Medical Devices | Full time employees 15 | Website https://heartsciences.com |
Full time employees 15 | Website https://heartsciences.com | ||
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to enhance its clinical utility. It is developing artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction and conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.